Novo invested in liver disease drug developer Mirum Pharmaceuticals as part of the round while Shire acquired an equity stake in the startup through a licensing deal.

US-based liver disease treatment developer Mirum Pharmaceuticals raised $120m yesterday in a series A round led by venture capital firm New Enterprise Associates (NEA) that included pharmaceutical firm Novo. Hedge fund sponsor Deerfield Management, growth equity firm Frazier Healthcare Partners, investment firm Rock Springs Capital and life sciences venture capital firms Pappas Capital and RiverVest…

The rest of this content is only accessible to Global Corporate Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.